Q2 2024 EPS Estimates for Sarepta Therapeutics, Inc. Decreased by Analyst (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Equities research analysts at Zacks Research reduced their Q2 2024 earnings per share estimates for shares of Sarepta Therapeutics in a research report issued on Monday, April 29th. Zacks Research analyst S. Ganoria now anticipates that the biotechnology company will earn ($0.06) per share for the quarter, down from their previous estimate of $0.04. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.13 per share. Zacks Research also issued estimates for Sarepta Therapeutics’ FY2026 earnings at $8.58 EPS.

Other analysts have also recently issued research reports about the company. Cantor Fitzgerald reiterated a “neutral” rating and set a $128.00 target price on shares of Sarepta Therapeutics in a research report on Thursday, February 29th. Wedbush reissued an “outperform” rating and issued a $224.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 29th. BMO Capital Markets began coverage on shares of Sarepta Therapeutics in a report on Wednesday, January 31st. They issued an “outperform” rating and a $170.00 target price on the stock. TheStreet raised Sarepta Therapeutics from a “d” rating to a “c-” rating in a research report on Monday, March 4th. Finally, Citigroup boosted their target price on Sarepta Therapeutics from $160.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, February 29th. Four research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $156.60.

Sarepta Therapeutics Trading Up 3.3 %

NASDAQ SRPT opened at $130.90 on Wednesday. The firm’s fifty day moving average price is $125.80 and its 200 day moving average price is $110.42. Sarepta Therapeutics has a 12 month low of $55.25 and a 12 month high of $159.89. The company has a debt-to-equity ratio of 1.32, a current ratio of 3.95 and a quick ratio of 3.45. The company has a market capitalization of $12.37 billion, a price-to-earnings ratio of -20.88 and a beta of 0.94.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a negative return on equity of 18.97% and a negative net margin of 43.11%. The firm had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. During the same period in the prior year, the company posted ($1.44) earnings per share. The firm’s quarterly revenue was up 63.1% compared to the same quarter last year.

Institutional Investors Weigh In On Sarepta Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in SRPT. Principal Securities Inc. purchased a new stake in Sarepta Therapeutics in the 4th quarter worth approximately $26,000. Mather Group LLC. acquired a new position in Sarepta Therapeutics in the first quarter valued at $28,000. Montag A & Associates Inc. purchased a new position in Sarepta Therapeutics during the third quarter worth about $30,000. Cary Street Partners Investment Advisory LLC boosted its stake in Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock worth $31,000 after buying an additional 154 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in Sarepta Therapeutics by 37.0% in the 1st quarter. GAMMA Investing LLC now owns 322 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 87 shares during the period. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Sarepta Therapeutics

In related news, Director Kathryn Jean Boor sold 761 shares of the firm’s stock in a transaction dated Monday, March 11th. The shares were sold at an average price of $122.93, for a total value of $93,549.73. Following the completion of the sale, the director now owns 7,516 shares in the company, valued at $923,941.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, Director Kathryn Jean Boor sold 761 shares of the company’s stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $122.93, for a total value of $93,549.73. Following the sale, the director now owns 7,516 shares in the company, valued at approximately $923,941.88. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 15,000 shares of Sarepta Therapeutics stock in a transaction on Friday, March 8th. The stock was sold at an average price of $123.25, for a total value of $1,848,750.00. Following the transaction, the director now directly owns 22,840 shares of the company’s stock, valued at $2,815,030. The disclosure for this sale can be found here. Insiders have sold a total of 22,096 shares of company stock valued at $2,739,419 in the last ninety days. 7.40% of the stock is currently owned by company insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.